Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 03 Feb 2023
Zai Lab announces NDA for sulbactam-durlobactam granted priority review by China’s NMPA
30 January 2023 - Zai Lab today announced that the Center for Drug Evaluation of China’s National Medical Products Administration has ...
Posted by Michael Wonder on 03 Feb 2023
Improved access to PBS medicines for pulmonary arterial hypertension
3 February 2023 - Access to pulmonary arterial hypertension PBS medicines has further improved as an outcome of the post-market review ...
Posted by Michael Wonder on 03 Feb 2023
Enhanced MSAC application now available for March 2023 deadline
3 February 2023 - The enhanced MSAC application forms are now available in the health products portal for use by ...
Posted by Michael Wonder on 03 Feb 2023
Strengthening Medicare for the future
3 February 2023 - The Albanese Government has released the Strengthening Medicare Taskforce report. ...
Posted by Michael Wonder on 02 Feb 2023
A prescription drug affordability board would lower prescription costs
1 February 2023 - Del. Rasoul is proposing Virginia create an independent panel of health care experts to review drug price ...
Posted by Michael Wonder on 02 Feb 2023
Drug prices increase 5.6% as Government ramps up pressure to lower costs
2 February 2023 - Restrained increases come as US implements the Inflation Reduction Act. ...
Posted by Michael Wonder on 02 Feb 2023
Enhertu launched as gastric cancer tertiary treatment in Korea, insurance benefits loading
2 February 2023 - In an environment where gastric cancer treatments are currently lacking, the approval of Enhertu (ingredient: trastuzumab ...
Posted by Michael Wonder on 02 Feb 2023
Medexus secures public reimbursement for Cuvposa in Quebec
1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...
Posted by Michael Wonder on 02 Feb 2023
Tezspire approved for self-administration in the US with a new pre-filled pen
2 February 2023 - First and only respiratory biologic without phenotype or biomarker limitations that offers the choice of administration ...
Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...
Posted by Michael Wonder on 02 Feb 2023
‘Enough sickness’ to share GP load among pharmacists, nurses
2 February 2023 - Pharmacy Guild of Australia president Trent Twomey says there is enough “demand and sickness” to allow ...
Posted by Michael Wonder on 02 Feb 2023
Calliditas receives conditional marketing authorisation from UK MHRA for Kinpeygo in IgA nephropathy
2 February 2023 - Calliditas Therapeutics today announced that the MHRA of the United Kingdom has granted conditional marketing authorisation for ...
Posted by Michael Wonder on 02 Feb 2023
Professor John Skerritt retirement
2 February 2023 - Today, Professor John Skerritt has announced his decision to retire from his position of Deputy Secretary ...
Posted by Michael Wonder on 02 Feb 2023
FDA approves first oral treatment for anaemia caused by chronic kidney disease for adults on dialysis
1 February 2023 - Today, the US FDA approved Jesduvroq tablets (daprodustat) as the first oral treatment for anaemia caused by ...
Posted by Michael Wonder on 01 Feb 2023
FLAG Therapeutics receives rare paediatric disease designation for FLAG-003 for the treatment of children with diffuse intrinsic pontine glioma
31 January 2023 - FLAG Therapeutics announced today that FLAG-003, an investigational small molecule therapy for the treatment of diffuse intrinsic ...